Safety and Effectiveness Analysis of Kivexa® (lamivudine/abacavir sulfate) in Human Immunodeficiency Virus Infected Korean Patients
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Lamivudine and abacavir sulfate are widely used nucleoside/tide reverse transcriptase inhibitors (NRTI) backbone agents, which are recommended in major international treatment guidelines. The fixed-dose combination of lamivudine and abacavir sulfate has been developed to contribute to low pill burden of antiretroviral therapy (ART) regimen and patient adherence. A mandatory post-marketing surveillance was conducted in Korea to monitor the safety of Kivexa (lamivudine 300 mg/abacavir 600 mg). Materials and Methods: An open label, multi-center, non-interventional post-marketing surveillance was conducted to monitor the safety of Kivexa from July 2011 to July 2017 in 23 hospitals in Korea. Subjects over 12 years old taking Kivexa per prescribing information were enrolled. The primary outcome was defined as the occurrence of any adverse events during the study period. Secondary outcomes included the occurrence of adverse drug reaction, the occurrence of serious adverse events and the effectiveness of Kivexa. Results: A total of 600 patients from 23 hospitals were enrolled within the 6 years of study. The total observation period was 1,004 person-years. Three hundred and ten patients reported 674 adverse events. The incidence of upper respiratory infection (65 cases, 10.9%) was the highest, followed by diarrhea (20 cases, 3.3%), and nausea (18 cases, 3.0%). 109 subjects reported 71 events of adverse drug reactions, and the most common reaction was nausea in 2.33% of the subjects. Thirty-one subjects reported serious adverse events, none of them were considered drug related. From the total of 600 subjects, excluding 48 subjects who were ‘effectiveness unassessable’ by investigators, 552 patients were eligible for the subjective effectiveness analysis. 459 (83.2%) were evaluated as ‘improved’. Proportion of subjects whose human immunodeficiency virus-RNA is <50 copies/ml was 61.2% (309/505) at the beginning of observation and increased to 91.9% (464/505) at the end of study period. Conclusions: The post-marketing surveillance showed the safety of Kivexa in HIV-1 patients in Korea. Ischemic cardiovascular events and hypersensitivity associated with Kivexa were few. There was no significant new safety information. This data may be helpful in implementing Kivexa and lamivudine/abacavir sulfate containing drugs in Korea.
Abstract
Background: Lamivudine and abacavir sulfate are widely used nucleoside/tide reverse transcriptase inhibitors (NRTI) backbone agents, which are recommended in major international treatment guidelines. The fixed-dose combination of lamivudine and abacavir sulfate has been developed to contribute to low pill burden of antiretroviral therapy (ART) regimen and patient adherence. A mandatory post-marketing surveillance was conducted in Korea to monitor the safety of Kivexa (lamivudine 300 mg/abacavir 600 mg). Materials and Methods: An open label, multi-center, non-interventional post-marketing surveillance was conducted to monitor the safety of Kivexa from July 2011 to July 2017 in 23 hospitals in Korea. Subjects over 12 years old taking Kivexa per prescribing information were enrolled. The primary outcome was defined as the occurrence of any adverse events during the study period. Secondary outcomes included the occurrence of adverse drug reaction, the occurrence of serious adverse events and the effectiveness of Kivexa. Results: A total of 600 patients from 23 hospitals were enrolled within the 6 years of study. The total observation period was 1,004 person-years. Three hundred and ten patients reported 674 adverse events. The incidence of upper respiratory infection (65 cases, 10.9%) was the highest, followed by diarrhea (20 cases, 3.3%), and nausea (18 cases, 3.0%). 109 subjects reported 71 events of adverse drug reactions, and the most common reaction was nausea in 2.33% of the subjects. Thirty-one subjects reported serious adverse events, none of them were considered drug related. From the total of 600 subjects, excluding 48 subjects who were ‘effectiveness unassessable’ by investigators, 552 patients were eligible for the subjective effectiveness analysis. 459 (83.2%) were evaluated as ‘improved’. Proportion of subjects whose human immunodeficiency virus-RNA is <50 copies/ml was 61.2% (309/505) at the beginning of observation and increased to 91.9% (464/505) at the end of study period. Conclusions: The post-marketing surveillance showed the safety of Kivexa in HIV-1 patients in Korea. Ischemic cardiovascular events and hypersensitivity associated with Kivexa were few. There was no significant new safety information. This data may be helpful in implementing Kivexa and lamivudine/abacavir sulfate containing drugs in Korea.
참고문헌 (23)
- Saag MS, "Antiretroviral drugs for treatment and prevention of HIV infection in adults : 2018 recommendations of the international antiviral society-USA panel", JAMA, 320, pp.379~396 (2018)
- "Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV"[URL]
- 대한에이즈학회, "The 2015 Clinical Guidelines for the Diagnosis and Treatment of HIV", AIDS in HIV-Infected Koreans, 2015, pp.47(3), 205~211[DOI]
- Walmsley SL, "Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection", N Engl J Med, 369, pp.1807~1818 (2013)
- Orrell C, "Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, openlabel, non-inferiority, phase 3b study", Lancet HIV, 4, pp.e536~e546 (2017)
- Smith KY, "Randomized, double-blind, placebo-matched, multicenter trial of abacavir", lamivudine or tenofovir, ritonavir for initial HIV treatment, pp.AIDS, 2009[DOI]
- "WHO-ART 092"[URL]
- "The use of the WHO-UMC system for standardised case causality assessment"[URL]
- "Annual report on the notified HIV/AIDS in Korea 2014"[URL]
- "Annual report on the notified HIV/AIDS in Korea 2015"[URL]
- Boettiger DC, "Trends in first-line antiretroviral therapy in Asia: results from the TREAT Asia HIV observational database", PLoS One, 9, pp.e106525~ (2014)
- 김민정, "Comparison of Antiretroviral Regimens: Adverse Effects and Tolerability Failure that Cause Regimen Switching", Infection and Chemotherapy, 47(4), pp.231~238 (2015), 대한감염학회
- 안혜원, "Safety and Efficacy of Ziagen (Abacavir Sulfate) in HIV-Infected Korean Patients", Infection and Chemotherapy, 49(3), pp.205~212 (2017), 대한감염학회
- Rasmussen LD, "Risk of cerebrovascular events in persons with and without HIV : a Danish nationwide population-based cohort study", AIDS, 25, pp.1637~1646 (2011)
- Choi AI, "Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons", AIDS, 25, pp.1289~1298 (2011)
- Cruciani M, "Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data", AIDS, 25, pp.1993~2004 (2011)
- Ding X, "No association of abacavir use with myocardial infarction : findings of an FDA meta-analysis", J Acquir Immune Defic Syndr, 61, pp.441~447 (2012)
- Bannister WP, "Incidence of abacavir hypersensitivity reactions in euroSIDA", Antivir Ther, 13, pp.687~696 (2008)
- Hetherington S, "Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir", Clin Ther, 23, pp.1603~1614 (2001)
- Sun HY, "Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan", J Antimicrob Chemother, 60, pp.599~604 (2007)
- Park WB, "Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?", Clin Infect Dis, 48, pp.365~367 (2009)
- To SW, "HLA-B*5701 genetic screening among HIV-1infected patients in Hong Kong: is this a practical approach in Han-Chinese?", Int J STD AIDS, 24, pp.50~52 (2013)
- Orkin C, "An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe", Pharmacogenet Genomics, 20, pp.307~314 (2010)